Global InformationAmy Weinfeld Schulman information
Amy Weinfeld Schulman is an American healthcare biotech venture capitalist, trained as a lawyer, who serves as a managing partner at Polaris Partners.[1][2][3] She focuses on investing in healthcare companies and early-stage biotech start-ups.[2][4] She also chairs the Board of Directors for Alnylam Pharmaceuticals (NASDAQ: ALNY)[5] and ByHeart,[6][7] and represents Polaris as a director for Kallyope, Thirty Madison, QurAlis, and Larkspur.[8] She also practiced as a lawyer.
- ^ "Amy Schulman | Polaris Partners". Retrieved 2024-03-22.
- ^ a b "Ms. Amy Schulman - Board of Trustees". board.caltech.edu. Retrieved 2024-03-22.
- ^ "Amy Schulman Elected as New Caltech Trustee". California Institute of Technology. 2023-09-13. Retrieved 2024-03-22.
- ^ "Amy Schulman '89 | Yale Law School". law.yale.edu. Retrieved 2024-03-22.
- ^ "Alnylam Elects Amy Schulman to its Board of Directors". fiercepharma.com.
- ^ ByHeart. "ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category". www.prnewswire.com (Press release). Retrieved 2024-03-22.
- ^ "ByHeart adds Amy Schulman and Hemi Zucker to Board along with raising $70m Series A financing led by Polaris Partners, OCV Partners and D1 Capital Partners". talent4boards.com.
- ^ "Amy Schulman". www.astp4kt.eu. Retrieved 2024-03-22.